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1. Introduction 
Alzheimer’s disease (AD) represents the so-called “storage disorder” of amyloid β (Aβ). The 
AD brain contains soluble and insoluble Aβ, both of which have been hypothesized to 
underlie the development of cognitive deficits or dementia (1-3). The steady-state level of 
Aβ is controlled by the generation of Aβ from its precursor, the degradation of Aβ within 
the brain, and transport of Aβ out of the brain. The imbalance among three metabolic 
pathways results in excessive accumulation and deposition of Aβ in the brain, which may 
trigger a complex downstream cascade (e.g., primary amyloid plaque formation or 
secondary tauopathy and neurodegeneration) leading to memory loss or dementia in AD. 
Accumulated lines of evidence indicate that such a memory loss represents a synaptic 
failure caused directly by soluble Aβ oligomers (AβOs) (4-6), whereas amyloid fibrils may 
cause neuronal injury indirectly via microglial activation (7). Many attentions are paid to 
understand the mechanism underlying the neurotoxic action of AβOs so far. However, the 
exact metabolic conditions controlling the in vivo generation of soluble AβOs has been out of 
attention.  
Several lines of evidence indicated that lipidic environments in the central nervous 
system (CNS) represent one of the prevailing metabolic conditions. We then 
hypothesized that an alteration of the lipoprotein-soluble Aβ interaction in the CNS is 
capable of initiating and/or accelerating the cascade favoring Aβ assembly (8). We found 
that dissociation of Aβ42 from lipoprotein in the cerebrospinal fluid from AD accelerates 
Aβ42 assembly (9). Thus, lipoprotein is a key molecule to maintain monomeric soluble 
Aβ42 in CNS. 
In this chapter, we review the issue regarding how lipoprotein and apolipoproteins 
contribute to physiological metabolic conditions. Then, we focus on how they constitute the 
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AD-related metabolic conditions in the CNS. We are certain that these points of view 
introduce a novel approach to find a therapeutic intervention for AD. 
2. Lipoproteins, apolipoproteins, and Aβ metabolism in the CNS 
In the CNS, we need to be aware that cholesterol metabolism is quite different from that 
in systemic circulation. Lipidic environments in the CNS were regulated by HDL-like 
lipoproteins, mainly lipidated apolipoprotein E (apoE), which is in charge of cholesterol 
transport to and from neurons (10, 11). This is also the case in lipidated apolipoprotein J 
(apoJ) (12). In addition to lipid trafficking, apoE or apoJ as a form of HDL-like lipoprotein 
plays a major role in Aβ metabolism in the CNS. Both apolipoproteins are well known as 
major carrier proteins for Aβ (13-17). Interestingly, transgenic mouse models of AD (apoE-
/-/apoJ-/-) revealed that both apolipoproteins regulate in a cooperative manner the 
clearance and the deposition of Aβ in brain (18). The hypothetical pathways involved in 
the clearance of CNS Aß are efflux of Aß into the plasma via blood-brain barrier (BBB). 
Two lipoprotein-receptors, LRP-1 and LRP-2, seem to be responsible for efflux of 
lipoprotein-free or lipoprotein-associated (apoJ-associated) Aß from the brain to blood, 
respectively (19). In vivo relevance of LRP-1-mediated Aß transport has been confirmed in 
transgenic mice expressing low LRP-1-receptor and APP, which develops extensive Aß 
accumulation much faster than transgenic mice expressing high level of APP (20). 
Reduced expression of brain endotherial LRP-1 was also observed in AD patients, which 
was associated with impaired Aß clearance and cerebrovascular accumulation. LPR-2 
appeared to function bi-directionally (influx vs efflux) at BBB. In contrast to LRP2-
mediated influx (21), LPR2-mediated efflux of brain Aß was actively operated under 
physiological concentration of either Aß or apoJ (19). Interestingly, a recent study shows 
that apoE4 binding to Aß redirects its clearance from LRP-1 to VLDLR, which resulted in 
slower efflux of brain Aß than LRP-1 (22). In contrast, apoE2-Aß and apoE3-Aß complexes 
are cleared at BBB via both LPR-1 and VLDLR at a substantially faster rate than apoE4-Aß 
complexes(22). Impairment of the above-mentioned receptor-mediated clearance at BBB 
could contribute to the pathogenesis of AD. Alternatively, ApoE4-HDL shows less 
cholesterol exchange between lipid particles and the neuronal membrane as compared 
with apoE3-HDL (23), leading to altered membrane functions, e.g., signal transduction, 
enzyme activities, ion channel properties, and conformation of sAß peptides, which 
contribute to the disease-related metabolic conditions. Furthermore, when the generation 
of HDL-like lipoproteins in the AD mouse model is suppressed or overexpressed via the 
specific regulation of ATP-binding cassette A1 (ABCA1), Aβ deposition exhibits 
augmentation or reduction, respectively, which depends on the degree of ABCA1-
mediated lipidation of apoE in the CNS (24, 25). From these points of view, lipidic 
environments in the CNS represent one of the prevailing metabolic conditions. We 
hypothesized that an alteration of the lipoprotein-sAβ interaction in the CNS is capable of 
initiating and/or accelerating the cascade favoring Aß assembly. Thus, we postulate that 
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lipoproteins or apolipoproteins may regulate the metabolic conditions controlling the in 
vivo generation of soluble AβOs. 
3. Aß is present in either lipoprotein-free or lipoprotein-associated form 
in brain parenchyma 
To assess the above-mentioned issue, we examined whether the dissociation of sAß from 
lipoprotein-particles occurs in the brain. The combination of size exclusion chromatography 
(SEC) and enzyme-linked immunosorbent assay (ELISA) revealed that the dissociation of 
sAß from lipoprotein-particles occurs in brain parenchyma and the presence of soluble 
dimeric lipoprotein-free Aß in AD brains (8). These findings may support the hypothesis 
that functionally declined lipoproteins may be major determinants in the production of 
metabolic conditions leading to higher levels of soluble dimeric SDS-resistant form of Aβ in 
AD brains (8, 26). At this moment, it remains undetermined whether dissociation of Aβ 
from lipoprotein or less association of Aβ to lipoproteins accounts for such a metabolic 
conditions. To further verify this hypothesis, we focused on the entorhinal cortex (EC), 
followed by biochemical analyses using an anti-oligomer specific antibody, namely 2C3 (9, 
27). Fifty brains obtained from healthy elderly are composed of three Braak NFT stages; 
Braak NFT stages I-II (n=35, normal control); Braak NFT stages III-IV (n=13, MCI stage); 
Braak NFT stages IV-V (n=2, AD stages). Immunoblot analysis of the delipidated EC 
employing monoclonal 2C3 revealed that the accumulation of soluble 12-mers precedes the 
appearance of neuronal loss or cognitive impairment, and is enhanced as the Braak 
neurofibrially tangle (NFT) stages progress, indicating that the ECs of AD patients indeed 
bear metabolic conditions that accelerate Aβ assembly.  
4. Aß is present in either lipoprotein-free or lipoprotein-associated form 
in cerebrospinal fluid (CSF)9 
The presence of lipoprotein-free sAβOs in CSF was also assessed in age-matched normal 
controls (NCs) and patients with Alzheimer’s disease (AD) by SEC and ELISA specific for 
either AβOs or AβMs. The SEC experiment using pooled CSF revealed that the dissociation 
of sAβMs from lipoprotein particles indeed occurs in CSF, which was lower in AD than in 
NCs. Furthermore, the SEC experiment using lipoprotein-depleted pooled CSF (LPD-CSF) 
confirmed the presence of oligomeric 2C3 conformers (4- to 35-mers), which appeared to be 
higher in AD patients than in NCs. To address the issue on the presence of any metabolic 
conditions favoring Aβ assembly, we compared the levels of lipoprotein-free sAβMs and 
sAβOs in LPD-CSF from the 12 sporadic AD patients and 13 NCs to evaluate the AβOs/ 
AβMs ratio (the O/M index). The levels of 2C3 oligomeric conformers composed of Aβ42 are 
significantly higher in AD patients than in NCs. The O/M index for either Aβ42 or Aβ40 is 
also significantly higher in AD patients than in NCs. Of note, the relative amounts of total 
lipoprotein-associated sAβMs (~70%) versus lipoprotein-free sAβMs (~30%) remained  




























Figure 1. Hypothetical metabolic conditions favoring Aβ assembly. Functionally declined lipoproteins 
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essentially unchanged in sporadic AD patients as compared with NCs. However, the 
relative amounts of lipoprotein-free Aβ42 was significantly lower in the sporadic AD 
patients (9.3 ± 3.9 %) than in NCs (13.2 ± 4.5 %), which is in accordance with our above-
mentioned finding that the level of oligomeric 2C3 conformers composed of Aβ42 was 
significantly elevated in AD patients. Thus, it is likely that the conversion of lipoprotein-free 
monomeric soluble Aβ42 into oligomeric assembly preferentially occurs in AD CSF, 
mirroring the disease-related metabolic conditions in the brain parenchyma.  
5. Summary 
We previously reported that ~90% of sAβMs that circulate in normal plasma is associated 
with lipoprotein particles (27). From the above data, it is plausible to assume that about 70% 
of CSF sAβMs is normally associated with lipoprotein particles, indicating that CNS 
constitutes a risky environment where the lipoproteins-sAβMs interaction is impaired, 
leading to Aβ assembly. From this point of view, a key molecule to maintain monomeric 
sAβ42 metabolism in CNS appears to be HDL-like lipoprotein particles. In this sense, the 
dissociation of sAβ42 from or the lack of association with HDL-like lipoprotein particles not 
only constitutes a potential mechanism to initiate and/or accelerate the cascade favoring 
Aβ42 assembly in the brain, but also results in a reduced clearance of physiological 
lipoprotein-associated sAβ42 peptides in the brain. Thus, above-mentioned CNS 
environments may strongly affect conformation of sAβ peptides, resulting in the conversion 
of sAβ42 monomers into sAβ42 assembly. The findings suggest that functionally declined 
lipoproteins may accelerate the generation of metabolic conditions leading to higher levels 
of sAβ42 assembly in the CNS. 
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